Welcome to the e-CCO Library!

P351: Bowel ultrasound is accurate in assessing disease activity in ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Allocca1*, G. Fiorino1, F. Furfaro1, S. Radice1, D. Gilardi1, L. Peyrin-Biroulet2, S. Danese1

Created: Thursday, 21 February 2019, 9:14 AM
P351: Do self-selected “Non-Transitioned” referrals from peadiatric services have lower treatment requirements?
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Shaikh O.1, Harvey P.*1, Cooney R.1, Muhammed R.2

Created: Wednesday, 20 February 2019, 10:36 AM
P351: Faecal calprotectin correlates well with extent of active endoscopic inflammation in patients with ulcerative colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

D. Chayut1, M. Kaplan2, Y. Chowers3, M. Waterman*3

Created: Friday, 22 February 2019, 9:49 AM
P351: MRI outcomes in perianal fistulising Crohn’s disease following anti-TNF-α therapy: a systematic review and meta-analysis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Lee*1, N. Ding2

Created: Friday, 22 February 2019, 9:41 AM
P351: SARS-CoV-2 infection and seroconversion in pediatric patients on biological therapy for Crohn’s disease: single tertiary center experience
Year: 2021
Source: ECCO'21 Virtual
Authors: Sładek, M.(1); Krucka-Kawalec , M.(2);Wojtas, E.(2);Jagielski , P.(3);Stochel-Gaudyn, A.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P351: Validation of anterior thigh ultrasound for screening of sarcopenia and elevated body fat in Inflammatory Bowel Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Mc Gettigan, N.(1,2)*;Saeidi, R.(1);Hanley, M.(3);Clarke, M.(1);O'Toole, A.(1);Morrin, M.(3);Boland, K.(1,4);
Created: Friday, 14 July 2023, 11:05 AM
P352 Infliximab-therapy intensification based on endoscopic activity suppresses treatment interruption among patients with Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

Y. Komaki1, S. Kanmura1, K. Yutsudo1, K. Kosuke2, F. Komaki1, A. Tanaka1, N. Nishimata3, Y. Sameshima4, F. Sasaki1, H. Ooi4, K. Tokushige5, Y. Sameshima3, A. Ido1

Created: Thursday, 30 January 2020, 10:12 AM
P352: A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn’s disease. The Cross Pennine study II
Year: 2021
Source: ECCO'21 Virtual
Authors: Lenti, M.V.(1,2);Dolby, V.(1);Clark, T.(1);Hall, V.(1);Tattersall, S.(1);Fairhurst, F.(1);Kenneth, C.(1);Walker, R.(1);Kemp, K.(1);Borg-Bartolo, S.(1);Limdi, J.(1);Taylor, J.(1);Townsend, T.(1);Subramanian, S.(1);Storey, D.(1);Assadsangabi, A.(1);Stansfield, C.(1);Smith, P.(1);Byrne, D.(1);De Silvestri, A.(1,3);Selinger, C.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P352: Assessment of the use of therapeutic drug monitoring of Adalimumab during maintenance therapy in children with inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Chavannes M.*1, Gervais F.1, Verreault A.2, Deslandres C.1, Jantchou P.2

Created: Wednesday, 20 February 2019, 10:36 AM
P352: Is diagnostic delay associated with the risk of colectomy in patients with ulcerative colitis? Results of a study of the Austrian IBD study group
Year: 2018
Source: ECCO '18 Vienna
Authors:

G. Novacek1*, H.P. Gröchenig2, T. Haas3, H. Wenzl4, P. Steiner5, R. Koch6, T. Feichtenschlager7, G. Eckhardt8, A. Mayer9, A. Kirchgatterer10, O. Ludwiczek11, R. Platzer12, P. Papay13, J. Gartner14, H. Fuchssteiner15, W. Miehsler16, P. Peters17, G. Reicht18, H. Vogelsang1, C. Dejaco1, T. Waldhör19

Created: Thursday, 21 February 2019, 9:14 AM
P352: Melanoma in a population-based Australian inflammatory bowel disease cohort
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

G. Hume*

Created: Friday, 22 February 2019, 9:49 AM
P352: Occurrence of moderate to severe anaemia and utilization and efficacy of intravenous iron therapies in a nationwide cohort of Inflammatory Bowel Disease patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Khan, N.(1,2)*;Patel, M.(1);Sundararajan, R.(1);
Created: Friday, 14 July 2023, 11:05 AM
P352: TDM of infliximab in IBD-patients: which pharmacokinetic marker to use?
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Berends*1,2, R. Mathôt1, A. Strik2, A. De Vries3, M. Löwenberg2, G. D'Haens2

Created: Friday, 22 February 2019, 9:41 AM
P352: Ustekinumab is associated with superior treatment persistence compared to vedolizumab in Crohn’s disease patients who failed to anti-TNF therapy: results from a Hungarian cohort study
Year: 2022
Source: ECCO'22
Authors: Bacsur, P.(1);Resál, T.(1);Miheller, P.(2);Szamosi, T.(3);Schäfer, E.(3);Sarlós, P.(4);Iliás, Á.(5);Szántó, K.J.(1);Rutka, M.(1);Bálint, A.(1);Fábián, A.(1);Bor, R.(1);Zoltán, S.(1);Matuz, M.(6);Molnár, T.(1);Farkas, K.(1);
Created: Friday, 11 February 2022, 3:52 PM
P353 Assessing compliance to screening for infectious diseases and vaccination in patients newly diagnosed with inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R. Pringle, A. Assadsangabi

Created: Thursday, 30 January 2020, 10:12 AM
P353: Aberrant brain structural large-scale connectome in Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Thomann*1, M. Griebe2, M. Ebert1, P. Thomann3, W. Reindl1

Created: Friday, 22 February 2019, 9:41 AM
P353: Agreement between patients, senior and junior physicians on disease activity and burden scoring in inflammatory bowel disease, using a tele-monitoring platform
Year: 2022
Source: ECCO'22
Authors: Mangia, M.(1,2);Giuffrida, E.(1,3);Figini, V.(4);Colombo, A.(1);Carli, E.(1);Mendolaro, M.(1);Lavagna, A.(1);Lia, C.(5);Bonina, M.(5);Martínez De Carnero, F.(5);Morello, E.(1);Cosimato, M.(1);Rocca, R.(1);Pagana, G.(4,5);Daperno, M.(1);
Created: Friday, 11 February 2022, 3:52 PM
P353: Clinical characteristics of ulcerative colitis associated with primary sclerosing cholangitis in Korea: An update
Year: 2018
Source: ECCO '18 Vienna
Authors:

S.-H. Lee1*, K. Chang1, M.-J. Kim2, E.M. Song1, S.W. Hwang1,3, D.-H. Yang1, J.-S. Byeon1, S.-J. Myung1, S.-K. Yang1,3, B.D. Ye1,3

Created: Thursday, 21 February 2019, 9:14 AM
P353: Endoscopy-based management within the first year after surgery decreases the risk of clinical and surgical postoperative recurrences in Crohn’s disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A.-L. Boucher1, B. Pereira2, S. Decousus3, M. Goutte1, 4, F. Goutorbe1, A. Dubois5, J. Gagnière5, C. Borderon6, J. Joubert3, D. Pezet5, M. Dapoigny1, P. Dechelotte3, G. Bommelaer1, 4, A. Buisson*1, 4

Created: Friday, 22 February 2019, 9:49 AM
P353: Long-term safety of adalimumab in patients with Crohn's disease: final data from PYRAMID registry
Year: 2017
Source: ECCO '17 Barcelona
Authors:

D'Haens G.*1, Reinisch W.2, Satsangi J.3, Loftus Jr. E.V.4, Panaccione R.5, Alperovich G.6, Kalabic J.7, Bereswill M.7, Arikan D.8, Petersson J.8, Robinson A.M.8

Created: Wednesday, 20 February 2019, 10:36 AM